Ceftaroline fosamil | TAK 599 | PPI 0903 | CAS#400827-46-5 | 229016-73-3

MedKoo Cat#: 314215 | Name: Ceftaroline fosamil

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Ceftaroline fosamil, also known as TAK 599 and PPI 0903, is an advanced-generation cephalosporin antibiotic. It is active against methicillin-resistant Staphylococcus aureus (MRSA) and Gram-positive bacteria. It retains the activity of later-generation cephalosporins having broad-spectrum activity against Gram-negative bacteria. It is currently being investigated for community-acquired pneumonia and complicated skin and skin structure infection.

Chemical Structure

Ceftaroline fosamil

CAS#400827-46-5 (acetate)

Theoretical Analysis

MedKoo Cat#: 314215

Name: Ceftaroline fosamil

CAS#: 400827-46-5 (acetate)

Chemical Formula: C24H25N8O10PS4

Exact Mass: 684.0103

Molecular Weight: 744.72

Elemental Analysis: C, 38.71; H, 3.38; N, 15.05; O, 21.48; P, 4.16; S, 17.22

Price and Availability

Size	Price	Availability	Quantity
5mg	USD 450.00	2 Weeks
10mg	USD 750.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

229016-73-3 (free form) 400827-46-5 (acetate)

Synonym

TAK 599; TAK599; TAK-599; PPI 0903; PP 0903; PPI-0903; T-91825; T 91825; T91825; Ceftaroline fosamil; Teflaro; Zinforo

IUPAC/Chemical Name

4-(2-(((6R,7R)-2-carboxy-7-((Z)-2-(ethoxyimino)-2-(5-(phosphonoamino)-1,2,4-thiadiazol-3-yl)acetamido)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl)thio)thiazol-4-yl)-1-methylpyridin-1-ium acetate

InChi Key

UGHHNQFYEVOFIV-VRDMTWHKSA-N

InChi Code

InChI=1S/C22H21N8O8PS4.C2H4O2/c1-3-38-26-13(16-25-21(43-28-16)27-39(35,36)37)17(31)24-14-18(32)30-15(20(33)34)12(9-40-19(14)30)42-22-23-11(8-41-22)10-4-6-29(2)7-5-10;1-2(3)4/h4-8,14,19H,3,9H2,1-2H3,(H4-,24,25,27,28,31,33,34,35,36,37);1H3,(H,3,4)/b26-13-;/t14-,19-;/m1./s1

SMILES Code

O=C(O)C(N1[C@@]([H])([C@@H](C1=O)NC(/C(C2=NSC(NP(O)(O)=O)=N2)=N\OCC)=O)SC3)=C3SC4=NC(C5=CC=[N+](C=C5)C)=CS4.O=C([O-])C

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO.

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 744.72 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Villa S, Escrihuela-Vidal F, Fernández-Hidalgo N, Escudero-Sánchez R, Cabezón I, Boix-Palop L, Díaz-Pollán B, Goikoetxea AJ, García-País MJ, Pérez-Rodríguez MT, Crespo Á, Buzón-Martín L, Sanz-Peláez O, Ramos-Merino L, Fiorante S, Muñoz P; Ceftaroline MRSA Group Spain GEIRAS-SEIMC. Ceftaroline for bloodstream infections caused by methicillin-resistant Staphylococcus aureus: a multicentre retrospective cohort study. Clin Microbiol Infect. 2024 Nov 23:S1198-743X(24)00551-2. doi: 10.1016/j.cmi.2024.11.022. Epub ahead of print. PMID: 39581546. 2: Caniff KE, Judd C, Lucas K, Goro S, Orzol C, Eshaya M, Al Musawa M, Veve MP, Rybak MJ. Heartfelt Impact: A Descriptive Analysis of Ceftaroline-Containing Regimens in Endocarditis due to Methicillin-Resistant Staphylococcus aureus. Infect Dis Ther. 2024 Dec;13(12):2649-2662. doi: 10.1007/s40121-024-01068-0. Epub 2024 Nov 2. PMID: 39487947; PMCID: PMC11582241. 3: Waked R, Coats L, Rosato A, Yen CF, Wood E, Diekema DJ, Rokas KE, Mercuro NJ. Clinical outcome of combination of vancomycin and ceftaroline versus vancomycin monotherapy for treatment of methicillin resistant Staphylococcus aureus bloodstream infection. BMC Infect Dis. 2024 Oct 28;24(1):1212. doi: 10.1186/s12879-024-10107-7. PMID: 39468491; PMCID: PMC11514869. 4: Shah S, Clarke L, Padival S. Ceftaroline combination therapy for methicillin resistant coagulase negative Staphylococcus bacteraemia and endocarditis. Eur J Hosp Pharm. 2024 Oct 26:ejhpharm-2024-004334. doi: 10.1136/ejhpharm-2024-004334. Epub ahead of print. PMID: 39461729. 5: Hausman BS, Memic S, Cadnum JL, Zink EG, Wilson BM, Donskey CJ. Effect of Ceftaroline, Ceftazidime/Avibactam, Ceftolozane/Tazobactam, and Meropenem/Vaborbactam on Establishment of Colonization by Vancomycin-Resistant Enterococci and Klebsiella pneumoniae in Mice. Pathog Immun. 2024 Sep 24;9(2):194-204. doi: 10.20411/pai.v9i2.711. PMID: 39345792; PMCID: PMC11432534. 6: Kim M, Ranganath N, Chesdachai S, Stevens RW, Sohail MR, Abu Saleh OM. Which trial do we need? Combination therapy with daptomycin plus ceftaroline versus standard-of-care monotherapy in the treatment of methicillin-resistant Staphylococcus aureus bacteraemia. Clin Microbiol Infect. 2025 Jan;31(1):18-21. doi: 10.1016/j.cmi.2024.08.011. Epub 2024 Sep 7. PMID: 39182576. 7: Ortiz-Mendiguren D, Crespo-Orta I, Miranda-Márquez M, Rivera-Bobe N, San Vicente-Morales G. Ceftaroline-Induced Thrombocytopenia: A Case Report. Cureus. 2024 Jul 27;16(7):e65488. doi: 10.7759/cureus.65488. PMID: 39071072; PMCID: PMC11282444. 8: Ferry T, Gogos C, Soriano A, Blasi F, Ansari W, Kantecki M, Schweikert B, Luna G, Bassetti M. Real-World Use and Treatment Outcomes of Ceftaroline Fosamil in Patients with Complicated Skin and Soft Tissue Infection: A Multinational Retrospective Study. Infect Drug Resist. 2024 Jul 4;17:2773-2783. doi: 10.2147/IDR.S455515. PMID: 38979062; PMCID: PMC11230118. 9: Siegrist EA, Sassine J. Ceftaroline in CNS and ocular infections: a case series. JAC Antimicrob Resist. 2024 Jun 17;6(3):dlae095. doi: 10.1093/jacamr/dlae095. PMID: 38887612; PMCID: PMC11180797. 10: Soriano A, Bassetti M, Gogos C, Ferry T, de Pablo R, Ansari W, Kantecki M, Schweikert B, Luna G, Blasi F. Ceftaroline fosamil treatment patterns and outcomes in adults with community-acquired pneumonia: a real-world multinational, retrospective study. JAC Antimicrob Resist. 2024 May 27;6(3):dlae078. doi: 10.1093/jacamr/dlae078. PMID: 38803385; PMCID: PMC11128847. 11: Cabanilla MG, Bernauer ML, Briski MJ, Atallah LM, Koury J, Thompson CM, Rodriguez CN, Jakeman B, Byrd TF. A Retrospective Cohort Study Comparing Dual Therapy With Ceftaroline With Vancomycin or Daptomycin Monotherapy for High- Grade or Persistent MRSA Bacteremia. J Pharm Technol. 2024 Jun;40(3):134-141. doi: 10.1177/87551225241227796. Epub 2024 Jan 31. PMID: 38784026; PMCID: PMC11110729. 12: Cabanilla MG, Bernauer ML, Atallah LM, Briski MJ, Koury J, Thompson CM, Rodriguez CN, Jakeman B, Byrd TF. Short versus long duration of ceftaroline combination therapy and outcomes in persistent or high-grade MRSA bacteremia: A retrospective single-center study. PLoS One. 2024 May 20;19(5):e0304103. doi: 10.1371/journal.pone.0304103. PMID: 38768130; PMCID: PMC11104650. 13: Alsowaida YS, Alsolami A, Almangour TA. Daptomycin and ceftaroline combination for the treatment of persistent methicillin-resistant Staphylococcus aureus bloodstream infections: a case series and literature review. J Chemother. 2024 Nov;36(7):540-545. doi: 10.1080/1120009X.2024.2340877. Epub 2024 Apr 12. PMID: 38606836. 14: Hammond J, Benigno M, Bleibdrey N, Ansari W, Nguyen JL. Ceftaroline Fosamil for the Treatment of Methicillin-Resistant Staphylococcus Aureus Bacteremia: A Real-World Comparative Clinical Outcomes Study. Drugs Real World Outcomes. 2024 Jun;11(2):273-283. doi: 10.1007/s40801-024-00422-5. Epub 2024 Apr 2. PMID: 38564101; PMCID: PMC11176132. 15: Hicks AS, Dolan MA, Shah MD, Elwood SE, Platts-Mills JA, Madden GR, Elliott ZS, Eby JC. Early Initiation of Ceftaroline-Based Combination Therapy for Methicillin-resistant Staphylococcus aureus Bacteremia. Res Sq [Preprint]. 2024 Mar 15:rs.3.rs-4095478. doi: 10.21203/rs.3.rs-4095478/v1. PMID: 38559201; PMCID: PMC10980158. 16: Chen L, Shashkina E, Kurepina N, Calado Nogueira de Moura V, Daley CL, Kreiswirth BN. In vitro activity of cefoxitin, imipenem, meropenem, and ceftaroline in combination with vaborbactam against Mycobacterium abscessus. Antimicrob Agents Chemother. 2024 May 2;68(5):e0017424. doi: 10.1128/aac.00174-24. Epub 2024 Apr 1. PMID: 38557171; PMCID: PMC11064484. 17: van Os W, Pham AD, Eberl S, Minichmayr IK, van Hasselt JGC, Zeitlinger M. Integrative model-based comparison of target site-specific antimicrobial effects: A case study with ceftaroline and lefamulin. Int J Antimicrob Agents. 2024 May;63(5):107148. doi: 10.1016/j.ijantimicag.2024.107148. Epub 2024 Mar 19. PMID: 38508535. 18: Policarpo S, Duro R, Pereira NR, Santos L. Daptomycin and Ceftaroline Combination Therapy in Complicated Endovascular Infections Caused by Methicillin-Resistant Staphylococcus epidermidis. Cureus. 2024 Feb 13;16(2):e54134. doi: 10.7759/cureus.54134. PMID: 38487127; PMCID: PMC10938187. 19: Urbach H, Sileo N, Lerma S, Nguyen K, Sosa Soto G, Nielsen M, Heiderich A, Holsapple J, Vuppula S, Campbell JI. Ceftaroline for Central Nervous System Infections: Case Report of a Young Infant, and Scoping Review. Pediatr Infect Dis J. 2024 Jul 1;43(7):663-668. doi: 10.1097/INF.0000000000004310. Epub 2024 Mar 4. PMID: 38451889. 20: Magrini E, Rando E, Del Giacomo P, Matteini E, Leanza GM, Sanmartin F, Carbone A, Maiuro G, Dusina A, Cingolani A. Cerebrospinal fluid drain infection caused by pandrug-resistant Staphylococcus epidermidis successfully treated with ceftaroline in combination with fosfomycin and vancomycin. Diagn Microbiol Infect Dis. 2024 May;109(1):116205. doi: 10.1016/j.diagmicrobio.2024.116205. Epub 2024 Feb 2. PMID: 38422663.